Directed differentiation of human embryonic stem (hES) cells and human induced pluripotent stem (hiPS) cells captures in vivo developmental pathways for specifying lineages in vitro, thus avoiding perturbation of the genome with exogenous genetic material. Thus far, derivation of endodermal lineages has focused predominantly on hepatocytes, pancreatic endocrine cells and intestinal cells [1] [2] [3] [4] [5] . The ability to differentiate pluripotent cells into anterior foregut endoderm (AFE) derivatives would expand their utility for cell therapy and basic research to tissues important for immune function, such as the thymus; for metabolism, such as thyroid and parathyroid; and for respiratory function, such as trachea and lung. We find that dual inhibition of transforming growth factor (TGF)-b and bone morphogenic protein (BMP) signaling after specification of definitive endoderm from pluripotent cells results in a highly enriched AFE population that is competent to be patterned along dorsoventral and anteroposterior axes. These findings provide an approach for the generation of AFE derivatives.
l e t t e r s
Directed differentiation of human embryonic stem (hES) cells and human induced pluripotent stem (hiPS) cells captures in vivo developmental pathways for specifying lineages in vitro, thus avoiding perturbation of the genome with exogenous genetic material. Thus far, derivation of endodermal lineages has focused predominantly on hepatocytes, pancreatic endocrine cells and intestinal cells [1] [2] [3] [4] [5] . The ability to differentiate pluripotent cells into anterior foregut endoderm (AFE) derivatives would expand their utility for cell therapy and basic research to tissues important for immune function, such as the thymus; for metabolism, such as thyroid and parathyroid; and for respiratory function, such as trachea and lung. We find that dual inhibition of transforming growth factor (TGF)-b and bone morphogenic protein (BMP) signaling after specification of definitive endoderm from pluripotent cells results in a highly enriched AFE population that is competent to be patterned along dorsoventral and anteroposterior axes. These findings provide an approach for the generation of AFE derivatives.
Directed differentiation of pluripotent stem cells into a variety of cell types opens a promising avenue for cell replacement therapy and provides a powerful tool for basic research 4 . ES cells are derived from the inner cell mass of the blastocyst and can be maintained in a pluri potent state by defined conditions. Furthermore, adult somatic cells can be reprogrammed into a pluripotent state (hiPS cells), paving the way for the generation of patientspecific pluripotent cells 6 .
Most efforts at generating endoderm derivatives from human pluripotent cells have focused on midgut (pancreatic endocrine cells) and posterior foregut (hepatocyte) cell types [1] [2] [3] [4] 7 . However, several clinically relevant cell types originate from AFE, the most rostral aspect of the endoderm. The caudal region of the AFE gives rise to trachea and lung 8 . The generation of respiratory tissue may allow cellular replacement therapies for respiratory disease. Rostral to the lung field is the pharyngeal endoderm, which forms four paired outcroppings, called pharyngeal pouches 9 . These develop into spe cific organs: eustachian tube and tympanic membrane (first pouch), palatine tonsils (second pouch), thymus (anterior third pouch), par athyroids (dorsal third and fourth pouch) and parafollicular C cells of the thyroid (fourth pouch). The thyroid body develops from the floor of the pharynx 9 . Several of these organs are excellent candidates for cellular replacement therapy. The thymus is the site of production of T lymphocytes 10 . Thymic function is severely affected by allogeneic hematopoietic stem cell transplantation, because of both pretrans plant conditioning regimens and posttransplant graftversushost disease, leading to profound defects in Tcell reconstitution 11 . As the thymus involutes with age, older transplant recipients would particularly benefit from thymic replacement therapy. In addition, the thymus is congenitally absent in nude/severe combined immuno deficient (SCID) and DiGeorge syndromes 10 . Moreover, autoimmune, congenital or acquired hypothyroidism and genetic or iatrogenic hypoparathyroidism may be treatable by replacement with tissues derived from ES or iPS cells.
Efforts at generating AFEderived cells have met with little success, although upregulation of thymus 12, 13 , thyroid 14 , parathyroid 15 or lung markers 16 in differentiating ES cells either after specification of defini tive endoderm or in mixedlineage embryoid bodies has been reported. However, these reports relied on drug selection, did not quantify the efficiency of induction or did not determine the presence of alternative lineages. Because cell fate is established through sequential and increas ingly lineagerestricted progenitors 4, 8 , we hypothesized that the failure to specify these cell types with high efficiency in vitro is due to the inability to induce AFE from endoderm. Therefore, we developed a strategy to generate AFE from human pluripotent cells.
Definitive endoderm, one of the three germ layers of the embryo proper, is induced from ES cells by high concentrations of activin A, mimicking nodal signaling during gastrulation 6 . Examination of this process in the hES cell line HES2 by quantitative PCR revealed a transcriptional cascade in which the primitive streak marker MIXL1 and then the endodermal transcription factors SOX17 and FOXA2 are upregulated (Fig. 1a) 1, 2, 7, 8, 17 . After 4 d of exposure to activin A, >95% of the cells expressed the definitive endoderm mark ers CXCR4, cKIT and EPCAM (Fig. 1b) 17 . After gastrulation, the definitive endoderm forms a tube with distinct anteroposterior axis identity 8 . Within definitive endoderm, the pluripotency marker SOX2 reemerges as a foregut marker, whereas CDX2 identifies hindgut 18 . After activin A removal at day 5 of culture, we observed an increase in both CDX2 and SOX2 expression (Fig. 1a) , suggesting the generation l e t t e r s and TBX1 mRNA on day 9 in cultures treated on day 5 after induction of definitive endoderm (see upper left panel), with the factors listed in the lower left panel (n = 3 biological replicates; *, significantly different from all other conditions, P < 0.0001; one-way ANOVA). d0, prior to start of differentiation; d5, day 5. (d) Expression of SOX2 and PAX9 on day 9 in cultures treated on day 5, after induction of definitive endoderm, with NOGGIN/SB-431542 (SB) in the presence or absence of sFRP3 (*, P < 0.05, n = 3 biological replicates). (e) Expression of BRACHYURY and PAX6 mRNA at day 9 in hES cells differentiated as previously described to neurectoderm (day 1 addition of NOGGIN/SB-431542), or after induction of endoderm (endoderm induction until day 5, followed by addition of NOGGIN/SB-431542). For BRAYCHURY, day 3.5 hES cells exposed to activin A and undergoing gastrulation served as a positive control (*, P < 0.0001, n = 3 experiments consisting each of three biological replicates). Following the generation of a CXCR4 + EPCAM + population in embryoid bodies exposed to activin A, the embryoid bodies were dissociated and plated as a monolayer. We tested the addition of 24 combinations of morphogens and inhibitors at day 5 (Fig. 1c) , and used expression of FOXA2, SOX2, CDX2, TBX1 (endoderm anterior to the stomach) 9, 18, 19 and PAX9 (pharyngeal endoderm) 10, 19 as read outs of cellular identity at day 9 of culture. Only in the combined presence of NOGGIN, a physiological inhibitor of BMP signaling, and SB431542, a pharmacological inhibitor of activin A/nodal and TGFβ signaling, was SOX2 expression induced, CDX2 expression suppressed and FOXA2 expression maintained. Furthermore, only this condi tion induced strong expression of TBX1 and PAX9 (Fig. 1c) . During the activin A-induction stage, cell number increased 4.5 ± 1.9fold, and during the NOGGIN/SB431542 stage, the cells expanded another 1.4 ± 0.4fold. Notably, NOGGIN/SB431542 treatment was equally potent in two hiPS cell lines (HDF2 and HDF9), with induction of SOX2, PAX9 and TBX1 (Supplementary Fig. 1 ). Multiple FGF family members and WNT3a, consistent with their functions in development 5, 7, 20 , posteriorized definitive endoderm, as shown by increased CDX2 expression (Fig. 1c) . However, WNT antago nism through addition of soluble Frizzledrelated protein 3 (sFRP3) was not sufficient to induce SOX2 (Fig. 1c) . Furthermore, sFRP3 did not synergize with NOGGIN/SB431542, and even appeared detrimental for the induction of PAX9 and SOX2 (Fig. 1d) . The timing of the addition of NOGGIN/SB431542 was critical, as only treat ment immediately after the generation of a uniform CXCR4 + cKIT + or CXCR4 + EPCAM + population at day 5/6 induced a SOX2 + FOXA2 + population at day 9. Earlier administration abrogated gastrulation, and later administration failed to downregulate the posterior marker CDX2 (data not shown).
FOXA2 is also expressed in the notochord (mesoderm), and FOXA2 and SOX2 are coexpressed by the hindbrain floorplate (neurecto derm) 21, 22 . Furthermore, direct application of NOGGIN/SB431542 to hES cells without prior endoderm induction by activin A leads to a neuroectodermal fate 23 . Therefore, we assayed for the presence of these alternative fates. As expected, the neuroectodermal marker PAX6 was expressed in cultures where NOGGIN/SB431542 was added at day 1, whereas BRACHYURY, a marker of the notochord and of gastrulating cells, was expressed during early endoderm induction (Fig. 1e) . Neither BRACHYURY nor PAX6 were expressed in defini tive endoderm exposed to NOGGIN/SB431542 (Fig. 1e) , indicating that NOGGIN/SB431542 treatment of activin A-induced definitive endoderm specifies only AFE.
To further assess whether the NOGGIN/SB431542induced endodermal cells were distinct from previously described endodermal lineages, we compared day 9 NOGGIN/SB431542treated cultures with day 9 cultures grown under conditions favoring a hepatic (poste rior foregut) fate. The latter has been previously shown to require BMP 4 and bFGF after activin A induction of endoderm 2 . The expression of CDX2, the hindgut marker EVX1, the liver markers CREB313 and CEBPA, as well as ODD1, a stomach domain marker 18 , was higher in the 'hepatic' conditions than in the NOGGIN/SB431542 conditions, and the reverse was true for the anterior markers TBX1, PAX9, SOX2 and FGF8, a marker within the endoderm specific for pharyngeal pouch endoderm 24 ( Fig. 1f) . Therefore, NOGGIN/SB431542 treatment specifies AFE cells that are distinct from those specified in hepatic conditions. Application of NOGGIN/SB431542 to activin A-induced defini tive endoderm yielded colonies of densely packed cells surrounding an empty lumenlike or cystlike opening. More than 90% of the cells were found in such colonies if plated at high density. Virtually all cells coexpressed SOX2 and FOXA2 (Fig. 2a, for HES2 cells, Fig. 2b for HDF9 iPS cells, Supplementary Fig. 2a for HDF9 and HDF2 hiPS cells, and Supplementary Fig. 2b for HES2 cells in Matrigel culture), although rare cells expressed only FOXA2 (Fig. 2a and Supplementary  Fig. 2a, arrows) . All colonies stained positive for TBX1, PAX9 and the pharyngeal endoderm marker FOXG1 (Fig. 2a, HES2 cells) . The typical colonies observed in NOGGIN/SB431542treated cultures were never seen when cells were cultured in media without added factors (Supplementary Fig. 2c ). In these conditions, >95% of cells expressed FOXA2, but only rarely were SOX2 + FOXA2 + cells observed (Supplementary Fig. 2c, arrows) . Colonies with this morphology were also never observed in hepatic conditions ( Supplementary  Fig. 2d ). Comparative immunofluorescence analysis of HES2derived endodermal cells cultured in parallel in either NOGGIN/SB431542 or hepatic conditions revealed that only NOGGIN/SB431542 cul tures were characterized by strong SOX2, PAX9 and TBX1 expression (Supplementary Fig. 2d ). 
Collectively, these expression data show that NOGGIN/SB431542 specifies a highly enriched population of cells with AFE phenotype in activin A-induced definitive endoderm. These findings are con sistent with the fact that mice null for the BMP antagonist Chordin display anterior truncations 25 and with the observation that activin A-induced endoderm contains a large fraction of CDX2 + posterior endoderm (Fig. 1a) .
To determine the potential in vivo of cells cultured in NOGGIN/ SB431542 conditions, we transplanted 10 6 cells under the kidney capsule of NOD/SCIDIl2rg −/− mice. Whereas undifferentiated HES2 cells generated teratomas containing cells derived from all three germ layers (Fig. 3a) , NOGGIN/SB431542treated cells produced growths lacking identifiable ectodermal or mesodermal elements (Fig. 3b) . We observed multiple luminal structures, lined either by pseudostratified epithelium (typical of upper airway epithelium) or a more disorganized epithelium containing one to three layers of nuclei (Fig. 3b) . The latter consistently stained for surfactant proteinC (SFTPC), a marker specific for type II alveolar cells in the lung (Fig. 3c and Supplementary Fig. 3a) . In hES cell-derived teratomas, no SFTPC staining was observed (data not shown). The remainder of the cells stained almost uniformly for FOXA2. However, except in the luminal structures, FOXA2 was confined to the cytoplasm, possibly owing to differentiation into FOXA2 − terminal AFE derivatives or to abnormal FOXA2 regulation in a xenograft (Fig. 3c) . Islands of cells expressing PAX9, as well as rare regions showing discrete nuclear speckles of AIRE (specific for medullary thymic epithelial cells 10 ), were also detected (Fig. 3c) . In hESderived teratomas, PAX9 was only observed in zones of cartilage formation and AIRE expression was not observed (data not shown). Collectively, these data suggest that the developmental potential of NOGGIN/SB431542induced definitive endoderm is largely limited to AFE derivatives in these conditions. Next, we attempted to further differentiate these cells. AFE under goes dorsoventral patterning, resulting in specification of lung buds, WNT3a (100 ng/ml), FGF10 (10 ng/ml), KGF (10 ng/ml) BMP4 (10 ng/ml), EGF (10 ng/ml) WNT3a (100 ng/ml), FGF10 (10 ng/ml), KGF (10 ng/ml) BMP4 (10 ng/ml), EGF (10 ng/ml) (WKFBE) (Fig. 3d) and consistent with the fact that Noggin is expressed dorsally in the AFE, whereas BMP4 is expressed ventrally 26 . In contrast, replac ing NOGGIN/SB431542 with WNT3a, KGF, FGF10, BMP4 and EGF (all factors, WKFBE) at day 7 of culture resulted in lower expression of SOX2 and induced the ventral markers NKX2.1, PAX1 and NKX2.5 at day 13 ( Fig. 3d for HES cells and Supplementary Fig. 3a ,b for HDF2 and HDF9 hiPS cells). Expression of the early thyroid marker, PAX8, was not observed, however, suggesting that NKX2.1 induction is indic ative of commitment to a lung, rather than a thyroid, fate (data not shown). Furthermore, P63, a marker of airway progenitor cells 26 , was strongly induced (Fig. 3d) , and the vast majority of the cells expressed the epithelial marker EPCAM (Supplementary Fig. 3c ). Addition of individual factors was not sufficient for this transcriptional induction (data not shown). Furthermore, only prior exposure to NOGGIN/SB 431542, and not to the hepatic cocktail or to media alone enabled subsequent upregulation of PAX1, NKX2.1 and NKX2.5 by WKFBE (Fig. 3e) , demonstrating that NOGGIN/SB431542 treatment of activin A-induced definitive endoderm is required for differentiation toward a ventral AFE fate. Timing of the WKFBE ventralization stimulus was critical, as only cultures treated at day 7, but not at day 9, were competent to express NKX2.1, PAX1 and NKX2.5 (data not shown). At this time, 92 ± 2% of the cells were FOXA2 + SOXA2 + (Fig. 3f,g ).
Immunofluorescence revealed that after induction in WKFBE, 37 ± 6% of cells expressed NKX2.1 ( Fig. 3h and Supplementary Fig. 3d ). During NOGGIN/SB431542 followed by WKFBE treatment of activin A-induced endoderm, cells expanded an additional 8.95 ± 3.3fold (Fig. 3g) . Thus, NOGGIN/SB431542induced AFE is uniquely com petent to respond to ventralization signals in vitro. Exposure of NOGGIN/SB431542induced AFE to WKFBE did not result in expression of terminal differentiation markers for thymus, parathyroid, thyroid or lung at day 13 or day 19 of culture (data not shown). As these cells had the potential to give rise to SFTPC + cells in vivo, we attempted to achieve lung specification in vitro. Consistent with a critical role for retinoic acid in early lung development 29 , addi tion of retinoic acid to the WKFBE cocktail decreased the expression of the pharyngeal pouch marker PAX1, but increased FOXP2, NKX2.1, GATA6 and FOXJ1, a constellation of markers suggestive of a lung fate 26 (Fig. 4a) . To enhance SFTPC induction, we added combinations of signaling agonists and antagonists at day 11 to AFE ventralized in the presence of retinoic acid. Among the >400 combinations exam ined, WNT3a + FGF10 + FGF7 induced high levels of SFTPC mRNA (Fig. 4b) at day 19, consistent with the developmental observations that FGF10 and Wnt signaling are critical for distal lung development 26 . To assess whether NOGGIN/SB431542induced AFE could generate pharyngeal pouch derivatives, we sought to pattern the cultures ven tralized with WKFBE in the absence of retinoic acid. Consistent with the requirement of sonic hedgehog (SHH) and FGF8 for parathyroid development 30 , addition of FGF8 or SHH to AFE cultures induced the parathyroidspecific marker GCM2 (Fig. 4b) . The effects of SHH and FGF8 were not additive, mirroring in vivo epistasis studies showing that Shh is upstream of Fgf8 in mouse pharyngeal pouch development 30 . Although we did not test all temporal and signaling permutations exhaustively, these data suggest that NOGGIN/SB431542induced cells are capable of differentiating into downstream lineages, includ ing the lung field and pharyngeal pouches.
Collectively, our data show that dual inhibition of BMP and TGFβ signaling in hES/hiPS cellderived definitive endoderm specifies a highly enriched AFE population, providing an in vitro approach for the directed differentiation of human pluripotent cells into cell types and tissues derived from the AFE in vivo.
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